The financing round is set to propel the advancement of the company’s lead CD22 UB-VV400 programme in oncology and autoimmune clinical trials. Credit: Mongkolchon Akesin/Shutterstock.

Umoja Biopharma has announced the closing of an oversubscribed $100m Series C financing round, which will enable the company to progress its in vivo chimeric antigen receptor (CAR)-T cell therapy pipeline.

Double Point Ventures and DCVC Bio jointly led the round, with participation from existing and new investors including ARK Invest, MPM Capital, Cormorant Asset Management, Qiming Venture Partners USA and Alexandria Venture Investments.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Proceeds from the round will help propel the advancement of the company’s lead CD22 UB-VV400 programme in several oncology and autoimmune clinical trials.

Umoja Biopharma co-founder and CEO Andrew Scharenberg stated: “We are pleased to announce the closing of our Series C financing with tremendous support from both new and existing investors who recognise Umoja’s potential to develop the industry’s first in vivo CAR T cell generating therapies — all in the hopes of increasing effectiveness, reducing barriers and expanding access to CAR T cell therapies.”

Senior adviser at Double Point Ventures, Dr Campbell Murray has been appointed as a new member of Umoja’s board of directors. Dr Phil Low of Purdue University will serve as chair of the company’s scientific advisory board and has been transitioned to the role of board observer.

Murray said: “It is an honour to co-lead this transformative investment round and to join Umoja’s board of directors.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Umoja’s groundbreaking work on in vivo CAR T cell therapies represents a new frontier in oncology and autoimmune treatment.”

Umoja Biopharma is engaged in the development of in vivo cell therapies. The company’s VivoVec in vivo gene delivery technology is designed to enable patients’ own immune systems to combat disease.

In January 2024, the company established a strategic partnership with AbbVie, aiming to develop new in-situ CAR-T cell therapy candidates targeting oncology indications.